cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Coherus Biosciences Inc
6 own
8 watching
Current Price
$0
$0.33
(7.31%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
358.17M
52-Week High
52-Week High
14.11
52-Week Low
52-Week Low
3.6
Average Volume
Average Volume
0.91M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
9.1545
iconMarket Capitalization358.17M
icon52-Week High14.11
icon52-Week Low3.6
iconAverage Volume0.91M
iconDividend Yield--
iconP/E Ratio9.1545
What does the Coherus Biosciences Inc do?
Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company's product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, nonsmall cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behcet's Disease, Crohn's Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Read More
How much money does Coherus Biosciences Inc make?
News & Events about Coherus Biosciences Inc.
Globe Newswire
3 months ago
- UDENYCA is the only pegfilgrastim therapy delivered in a convenient, easy-to-administer prefilled autoinjector to offer in-clinic and at-home administration options for cancer patients undergoing myelosuppressive chemotherapy - - An additional presentation, the UDENYCA proprietary on-body injector...
Globe Newswire
3 months ago
REDWOOD CITY, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that senior management will present at the following investor conferences in March. 43rd Annual Cowen Health Care Conference on Tuesday, March 7th at 2:10 p.m. ETBarclays 2023 ...
Globe Newswire
3 months ago
REDWOOD CITY, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced that its fourth quarter and full year 2022 financial results will be released after market close on Monday, March 6, 2023. Starting at 5:00 pm ET on March 6, 2023, Coherus ...
Globe Newswire
3 months ago
Final overall survival analysis of the JUPITER-02 trial shows first-line treatment with toripalimab plus chemotherapy significantly prolongs survival in patients with advanced NPCSHANGHAI, China and REDWOOD CITY, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi ...
Globe Newswire
3 months ago
- Q-Code assigned to CIMERLI for Medicare claims processing effective for dates of service on and after April 1, 2023 - - COHERUS Solutions patient services hub is available to facilitate successful access and reimbursement - REDWOOD CITY, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Coherus ...
Frequently Asked Questions
Frequently Asked Questions
What is Coherus Biosciences Inc share price today?
plus_minus_icon
Can Indians buy Coherus Biosciences Inc shares?
plus_minus_icon
How can I buy Coherus Biosciences Inc shares from India?
plus_minus_icon
Can Fractional shares of Coherus Biosciences Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Coherus Biosciences Inc stocks?
plus_minus_icon
What is today’s traded volume of Coherus Biosciences Inc?
plus_minus_icon
What is today’s market capitalisation of Coherus Biosciences Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Coherus Biosciences Inc?
plus_minus_icon
What percentage is Coherus Biosciences Inc down from its 52-Week High?
plus_minus_icon
What percentage is Coherus Biosciences Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.33
(7.31%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00